Notably, during the last few years, several studies have evaluated the action of in use treatments against MCM2. In particular, MCM2 is a therapeutic target of Trichostatin A in colon cancer cells [65], MCM2 has been proposed as therapeutic target of lovastatin in human non-small cell lung carcinomas [66], the combination of MCM2 silencing and carboplatin treatment may represent a novel therapeutic strategy to treat ovarian cancer [67]. This evidence concerns the gene MCM2 and ovarian carcinoma.